Man Group PLC : Form 8.3 - Quantum Pharma Plc FORM

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
17
Man Group PLC : Form 8.3 - Quantum Pharma Plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Full name of discloser: Man Group Plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):                                                                      N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:                                                                      Quantum Pharma plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
(e) Date position held/dealing undertaken:                                                                      03 nd October 2017
(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?      YES / NO / N/A If YES, specify which: Clinigen Group plc

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:   10p ordinary
    Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 0 0 0 0
(2) Cash-settled derivatives:   6,500,440 3.8437 0 0
(3) Stock-settled derivatives (including options) and agreements to purchase/sell: 0 0 0 0
       TOTAL: 6,500,440 3.8437 0 0

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)        Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale   Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (GBP)
10p ordinary CFD Increasing a long position 3,564 0.8100
10p ordinary CFD Increasing a long position 28,263 0.8100

(c)        Stock-settled derivative transactions (including options)

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercise

Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit
           

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
       

4.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
  None  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None  

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? YES/ NO
Date of disclosure: 04 th October 2017
Contact name: James Carr  
Telephone number: 02071447242

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Ipsen's Kayfanda® Receives EU Approval for Alagille Syndrome Treatment

Updated Category News Views 67

Kayfanda® Receives Approval for Treatment in the EU Ipsen has made a noteworthy advancement in pediatric healthcare with the recent authorization of Kayfanda® (odevixibat) in the European Union (EU). This innovative treatment specifically addresses cholestatic pruritus, a painful symptom linked to Alagille Syndrome, a rare liver disorder that affects children. This...

Continue Reading
Discover the Remarkable Returns of Vulcan Materials Stock

Updated Category News Views 144

Unveiling Vulcan Materials Company Stock Performance Vulcan Materials Co. (NYSE: VMC) has been a noteworthy performer in the stock market over the past 15 years, surpassing market expectations with a commendable annual return of 15.1%. This stock has consistently outperformed the market, achieving an admirable 2.86% advantage annually. With a current market capitalization...

Continue Reading
AeroPress Launches Premium Coffee Press with Elegant Design

Updated Category News Views 332

AeroPress introduced its Premium coffee press back in 2024, and you can bet the market was watching closely. With a retail price of $149.95, this isn’t just another brewing tool; it’s a statement piece designed for those who take their morning ritual seriously. Traders buzzed about how this could impact sales in a saturated market where every new gadget fights for...

Continue Reading
Investigation Update: Walgreens Boots Alliance Class Action Lawsuit

Updated Category News Views 327

Overview of the Walgreens Boots Alliance Class Action Levi & Korsinsky, LLP has raised awareness among investors regarding a class action securities lawsuit involving Walgreens Boots Alliance, Inc. This company, known for its extensive pharmaceutical and retail operations, is currently facing legal challenges that could significantly impact its investors. Class Definition...

Continue Reading
Savillex Strengthens Market Position with New Acquisition

Updated Category News Views 38

Savillex Acquires Optimum Processing to Enhance Offerings Thompson Street Capital Partners (TSCP) is proud to announce that its portfolio company, Savillex, has completed the acquisition of Optimum Processing, Inc. This strategic move is expected to elevate Savillex's position in the marketplace by combining its innovative fluid handling solutions with Optimum...

Continue Reading